Clinical Trials
15 trialsNCT02630693 2026-04-13
Two Different Schedules of Palbociclib + Second Line Endocrine Therapy in Estrogen Receptor Positive, HER2 Neg Advanced/Metastatic Breast Cancer
Canadian Cancer Trials Group
Phase 2 Completed
NCT02760030 2025-12-19
Endocrine Therapy Fulvestrant & Palbociclib or Aromatase Inhibitor Therapy in Treating Older Patients With Hormone Responsive Breast Cancer That Cannot Be Removed by Surgery
Ohio State University Comprehensive Cancer Center
Phase 2 Completed
NCT04352777 2025-07-20
Impact of Endocrine Therapy and Abemaciclib on Host and Tumor Immune Cell Repertoire/Function in Advanced ER+/HER2- Breast Cancer
Duke University
Phase 2 Completed
NCT02040857 2025-04-29
Palbociclib in Combination With Adjuvant Endocrine Therapy for Hormone Receptor Positive, HER2 Negative Invasive Breast Cancer
Dana-Farber Cancer Institute
Phase 2 Completed
NCT02188745 2024-07-17
POLLY
Dartmouth-Hitchcock Medical Center
Phase 2 Completed
NCT03477396 2024-02-20
Ribociclib and Aromatase Inhibitor in Treating Older Participants With Hormone Receptor Positive Metastatic Breast Cancer
City of Hope Medical Center
Phase 2 Completed
NCT04240106 2024-02-16
LUZERN
MedSIR
Phase 2 Completed
NCT00499083 2023-09-29
Paclitaxel, Cyclophosphamide & Doxorubicin, Autologous Dendritic Cells & Surgery in Stage II/III Breast Cancer (Women)
University of Nebraska
Phase 2 Completed
NCT00773695 2023-01-09
A Study of Bevacizumab (Avastin) in Combination With Neoadjuvant Treatment Regimens in Participants With Primary Human Epidermal Growth Factor Receptor 2 (HER2) Negative Breast Cancer
Hoffmann-La Roche
Phase 2 Completed
NCT00828854 2022-06-30
Study of the Effect of the Addition of SNDX-275 (Entinostat) to Continued Aromatase Inhibitor (AI) Therapy in Postmenopausal Women With ER+ Breast Cancer Whose Disease is Progressing
Syndax Pharmaceuticals
Phase 2 Completed
NCT01491737 2020-10-28
PERTAIN
Hoffmann-La Roche
Phase 2 Completed
NCT01446159 2020-06-02
Study of MEDI-573 Plus Standard Endocrine Therapy for Women With Hormone-sensitive Metastatic Breast Cancer
MedImmune LLC
Phase 2 Completed
NCT02970682 2019-07-12
STEM
Evgen Pharma
Phase 2 Completed
NCT01654185 2017-03-14
Dimethyldiguanide Combined With Aromatase Inhibitor (AI) in Metastatic Breast Cancer
Fudan University
Phase 2 Completed
NCT00119262 2014-05-15
Bevacizumab and Combination Chemotherapy in Patients With Lymph Node Positive Breast Cancer
National Cancer Institute (NCI)
Phase 2 Completed